BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31133226)

  • 1. [Not Available].
    Herms F
    Ann Dermatol Venereol; 2019 May; 146 Suppl 2():IIS22-IIS30. PubMed ID: 31133226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Paugam C; Dréno B
    Ann Dermatol Venereol; 2019 May; 146 Suppl 2():IIS31-IIS35. PubMed ID: 31133228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Velter C
    Ann Dermatol Venereol; 2019 May; 146 Suppl 2():IIS3-IIS9. PubMed ID: 31133227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Cribier B
    Ann Dermatol Venereol; 2019 May; 146 Suppl 2():IIS10-IIS15. PubMed ID: 31133224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actinic keratosis - review for clinical practice.
    de Oliveira ECV; da Motta VRV; Pantoja PC; Ilha CSO; Magalhães RF; Galadari H; Leonardi GR
    Int J Dermatol; 2019 Apr; 58(4):400-407. PubMed ID: 30070357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Perrot JL; Tognetti L; Habougit C; Biron Schneider AC; Couzan C; Rubegni P; Cinotti E;
    Ann Dermatol Venereol; 2019 May; 146 Suppl 2():IIS16-IIS21. PubMed ID: 31133225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.
    Jansen MHE; Kessels JPHM; Merks I; Nelemans PJ; Kelleners-Smeets NWJ; Mosterd K; Essers BAB
    Br J Dermatol; 2020 Oct; 183(4):738-744. PubMed ID: 31961446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daylight methyl-aminolevulinate photodynamic therapy versus ingenol mebutate for the treatment of actinic keratoses: an intraindividual comparative analysis.
    Genovese G; Fai D; Fai C; Mavilia L; Mercuri SR
    Dermatol Ther; 2016 May; 29(3):191-6. PubMed ID: 26799440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
    Philipp-Dormston WG
    Curr Probl Dermatol; 2015; 46():115-21. PubMed ID: 25561215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
    Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
    Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies.
    Schmitt AR; Bordeaux JS
    Clin Dermatol; 2013; 31(6):712-7. PubMed ID: 24160275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
    Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility of first-line actinic keratosis treatments in Finland.
    Soini EJ; Hallinen T; Sokka AL; Saarinen K
    Adv Ther; 2015 May; 32(5):455-76. PubMed ID: 26006101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology.
    Dirschka T; Gupta G; Micali G; Stockfleth E; Basset-Séguin N; Del Marmol V; Dummer R; Jemec GBE; Malvehy J; Peris K; Puig S; Stratigos AJ; Zalaudek I; Pellacani G
    J Dermatolog Treat; 2017 Aug; 28(5):431-442. PubMed ID: 27796187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The paradigm shift in treating actinic keratosis: a comprehensive strategy.
    Stockfleth E
    J Drugs Dermatol; 2012 Dec; 11(12):1462-7. PubMed ID: 23377517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.
    Gupta AK; Paquet M
    Br J Dermatol; 2013 Aug; 169(2):250-9. PubMed ID: 23550994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional treatment of actinic keratosis: an overview.
    Peris K; Fargnoli MC
    Curr Probl Dermatol; 2015; 46():108-14. PubMed ID: 25561214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.
    Sinclair R; Baker C; Spelman L; Supranowicz M; MacMahon B
    Australas J Dermatol; 2021 May; 62(2):119-123. PubMed ID: 32840870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current management of actinic keratoses.
    Shoimer I; Rosen N; Muhn C
    Skin Therapy Lett; 2010 May; 15(5):5-7. PubMed ID: 20505896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing the Challenges of Treating Actinic Keratosis.
    Kircik LH
    J Drugs Dermatol; 2019 May; 18(5):s160. PubMed ID: 31141861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.